How to buy Innoviva stock (INVA)

Innoviva is a biotechnology business based in the US. Innoviva shares (INVA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $18.42 – a decrease of 3.05% over the previous week. Innoviva employs 112 staff and has a trailing 12-month revenue of around $352.7 million.

Our top picks for where to buy Innoviva stock

Buy Innoviva stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Innoviva stock price (NASDAQ: INVA)

Use our graph to track the performance of INVA stocks over time.

Innoviva shares at a glance

• Key figures

Information last updated 2024-12-11.

Latest market close	$18.42
52-week range	$14.33 - $21.28
50-day moving average more info button	$19.54
200-day moving average more info button	$17.39
Wall St. target price	$19.00
PE ratio more info button	23.5625
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$0.80

Is it a good time to buy Innoviva stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Innoviva price performance over time

Historical closes compared with the close of $18.58 from 2024-12-13

1 week (2024-12-10)	-2.21%
1 month (2024-11-15)	-1.69%
3 months (2024-09-17)	-5.73%
6 months (2024-06-17)	14.98%

1 year (2023-12-15)	19.95%
2 years (2022-12-16)	45.50%
3 years (2021-12-17)	6.72%
5 years (2019-12-17)	32.15%

Is Innoviva stock undervalued or overvalued?

Valuing Innoviva stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Innoviva's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Innoviva's P/E ratio

Innoviva's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Innoviva shares trade at around 24x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Innoviva's PEG ratio

Innoviva's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.24. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Innoviva's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Innoviva's EBITDA

Innoviva's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $221.2 million.

The EBITDA is a measure of a Innoviva's overall financial performance and is widely used to measure a its profitability.

Innoviva financials

Revenue TTM	$352.7 million
Operating margin TTM	48.31%
Gross profit TTM	$276.1 million
Return on assets TTM	9.37%
Return on equity TTM	9.97%
Profit margin	18.31%
Book value	$10.68
Market Capitalization more info button	$1.2 billion

TTM: trailing 12 months

Innoviva share dividends

We're not expecting Innoviva to pay a dividend over the next 12 months.

Have Innoviva's shares ever split?

Innoviva's shares were split on a 1241:1000 basis on 2 June 2014 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1241 shares. This wouldn't directly have changed the overall worth of your Innoviva shares – just the quantity. However, indirectly, the new 19.4% lower share price could have impacted the market appetite for Innoviva shares which in turn could have impacted Innoviva's share price.

Innoviva share price volatility

Over the last 12 months, Innoviva's shares have ranged in value from as little as $14.33 up to $21.28. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innoviva's is 0.568. This would suggest that Innoviva's shares are less volatile than average (for this exchange).

Innoviva overview

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.

Frequently asked questions

null
What percentage of Innoviva is owned by insiders or institutions?
Currently 1.069% of Innoviva shares are held by insiders and 118.548% by institutions. How many people work for Innoviva?
Latest data suggests 112 work at Innoviva. When does the fiscal year end for Innoviva?
Innoviva's fiscal year ends in December. Where is Innoviva based?
Innoviva's address is: 1350 Old Bayshore Highway, Burlingame, CA, United States, 94010 What is Innoviva's ISIN number?
Innoviva's international securities identification number is: US45781M1018 What is Innoviva's CUSIP number?
Innoviva's Committee on Uniform Securities Identification Procedures number is: 88338T104